Lannett announces launch Of FDA approved Levothyroxine Tablets

▴ lannett-launches-fda-approved-levothyroxine-levorphanol-tablets
Lanett to introduce and market levothyroxine as well Levorphanol tablets

Lannett Company, Inc. today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies' recently announced interim exclusive supply and distribution agreement.

The companies also said they have prevailed in separate legal challenges by Cediprof's previous distributor of the product. Judges in two courts denied a request by the previous distribution partner for a temporary restraining order that sought to enjoin Cediprof from terminating the prior agreement and transferring distribution rights to Lannett.

Lannett said the rulings removed a potential hurdle for it to commence distributing the product in the U.S., notwithstanding any ongoing dispute with Cediprof's prior partner on the earlier termination.Cediprof, Inc. is a part of the Neolpharma Pharmaceutical Group family of companies.

The company also recently announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product.

Lannett entered into an exclusive U.S. distribution agreement for Levorphanol Tablets with Novitium Pharma, a U.S. based pharmaceutical company. Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.

"We are pleased to establish a new strategic relationship with Novitium Pharma, a private company with a growing portfolio of commercial products," said Tim Crew, chief executive officer of Lannett. "Novitium received FDA approval earlier this month of its Abbreviated New Drug Application (ANDA) for Levorphanol Tablets 2 mg, a product currently with a small number of competitors. Levorphanol Tablets 2 mg is a solid addition to our product offering."

Total U.S. sales for the 12 months ended May 2020 of Levorphanol Tablets 2 mg were approximately $60.9 million, according to IQVIA, although actual generic market values are expected to be lower.

Levorphanol Tablets 2 mg is the therapeutic equivalent to the reference listed drug, Levorphanol Tartrate Tablets 2 mg of Sentynl Therapeutics, Inc.

Levorphanol Tablets are included in the Opioid Analgesic Risk Evaluation and Mitigation Strategies (REMS) program. The FDA has determined that a REMS is necessary for all opioid analgesics intended for outpatient use to ensure that the benefits of these drugs continue to outweigh the risks. The Opioid Analgesic REMS is one strategy among multiple national and state efforts to reduce the risk of abuse, misuse, addiction, overdose and deaths due to prescription opioid analgesics.

Neolpharma Pharmaceutical Group engages in the research, development, production and distribution of generic medicines in the following therapeutic areas: CNS, oncology, metabolic disease, rheumatology and infectious diseases. Based in Mexico City, Mexico, Neolpharma Group has affiliates and operations in Puerto Rico, the U.S. and Latin America. 

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Tags : #Lannet #FDAApproval #levothyroxine #Levorphanol #NovitiumPharma #REMSProhram #Cediprof

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024